human
rhinovirus
hrv
picornavirida
frequent
caus
mild
upper
respiratori
tract
infect
common
cold
respons
half
case
common
cold
hrv
also
associ
sever
diseas
acut
otiti
media
children
sinus
adult
hrv
also
caus
sever
lower
respiratori
tract
infect
pneumonia
wheez
bronchiol
exacerb
asthma
chronic
obstruct
pulmonari
diseas
infant
children
well
fatal
pneumonia
elderli
immunocompromis
adult
although
hrvinduc
upper
respiratori
ill
often
mild
selflimit
socioeconom
impact
caus
medic
visit
school
work
absente
hrv
infect
consider
degre
inappropri
antibiot
use
signific
serotyp
hrv
becom
obstacl
develop
unifi
vaccin
therefor
high
need
develop
select
antivir
agent
novel
target
site
establish
effect
hrv
manag
strategi
tactic
current
approv
antivir
therapi
prevent
treatment
hrv
infect
plant
suggest
altern
sourc
antivir
product
larg
constitut
potenti
sourc
bioactiv
secondari
substanc
perceiv
gener
public
rel
safe
minim
impact
human
health
often
act
multipl
novel
target
site
much
effort
focus
plant
constitu
potenti
sourc
commerci
antivir
product
prevent
treatment
hrv
infect
screen
plant
antihrv
activ
methanol
extract
leav
giant
crapemyrtl
call
banaba
phillippin
lagerstroemia
speciosa
l
per
lythracea
shown
good
antivir
activ
toward
littl
inform
done
consid
potenti
use
l
speciosa
manag
hrv
although
plant
leav
possess
antidiabet
hypoglycem
antiobes
antioxid
antigout
antiinflammatori
antibacteri
activ
aim
studi
assess
cytotox
antivir
effect
hela
cell
three
hrv
serotyp
tannin
ellag
acid
l
speciosa
leav
compar
commerci
pure
ellag
acid
ribavirin
current
use
broadspectrum
antivir
agent
antivir
properti
mechan
action
constitu
elucid
use
sulforhodamin
b
srb
assay
realtim
revers
transcriptionpcr
sybr
green
dye
nmr
spectra
record
jnmecx
spectromet
jeol
tokyo
japan
mhz
respect
use
tetramethylsilan
intern
standard
chemic
shift
given
ppm
uv
spectra
obtain
methanol
biomat
spectrophotomet
thermo
spectron
rochest
ny
fourier
transform
infrar
ftir
spectra
nicolet
magna
seri
ii
spectromet
midac
atlanta
ga
mass
spectra
jeol
gsx
spectromet
silica
gel
mm
merck
darmstadt
germani
use
column
chromatographi
merck
precoat
silica
gel
plate
kieselgel
mm
use
analyt
thinlay
chromatographi
tlc
avp
highperform
liquid
chromatograph
shimadzu
kyoto
japan
use
isol
activ
principl
hela
atcc
human
epitheli
adenocarcinoma
cervix
cell
line
purchas
american
type
cultur
collect
atcc
manassa
va
cell
line
maintain
mem
supplement
fetal
bovin
serum
antibioticantimycot
humidifi
incub
atcc
atcc
atcc
purchas
atcc
three
hrv
propag
hela
cell
viru
titer
determin
cytopath
effect
cpe
hela
cell
express
cell
cultur
infect
dose
per
ml
describ
previous
airdri
leav
l
speciosa
purchas
local
giant
crapemyrtl
farm
philippin
certifi
botan
taxonomist
use
identifi
plant
voucher
specimen
l
deposit
research
institut
agricultur
life
scienc
colleg
agricultur
life
scienc
seoul
nation
univers
airdri
leav
kg
l
speciosa
pulver
extract
methanol
l
room
temperatur
day
filter
combin
filtrat
concentr
dryness
rotari
evapor
yield
g
dark
greenish
powder
extract
g
sequenti
partit
hexan
g
ethyl
acet
g
butanol
g
watersolubl
g
portion
subsequ
bioassay
organ
solventsolubl
portion
concentr
vacuum
watersolubl
portion
concentr
isol
activ
principl
viral
cpe
inhibit
assay
describ
previous
toward
hela
cell
use
ethyl
acetatesolubl
fraction
g
biolog
activ
tabl
chromatograph
cm
silica
gel
g
column
elut
gradient
chloroform
methanol
l
l
l
l
l
l
l
l
l
volum
provid
fraction
ml
figur
column
fraction
monitor
tlc
silica
gel
plate
develop
chloroform
methanol
volum
mobil
phase
fraction
similar
rf
valu
tlc
plate
pool
spot
detect
spray
sulfur
acid
heat
hot
plate
activ
fraction
g
pool
separ
chloroformsolubl
mg
nonsolubl
mg
fraction
activ
nonsolubl
fraction
separ
methanolsolubl
mg
nonsolubl
mg
fraction
activ
methanolsolubl
fraction
separ
tlc
plate
develop
volum
give
activ
fraction
mg
rf
separ
constitu
activ
fraction
highperform
liquid
chromatographi
perform
column
mm
id
mm
ec
nucleodex
alphapm
machereynagel
easton
pa
use
mobil
phase
methanol
water
volum
flow
rate
mlmin
chromatograph
separ
monitor
use
uv
detector
nm
final
activ
principl
mg
isol
retent
time
min
isol
obtain
green
amorph
powder
identifi
instrument
analys
includ
ms
nmr
mass
spectrum
exhibit
molecular
ion
mz
ir
absorpt
indic
presenc
phenol
hydroxyl
c
benzonoid
c
c
group
respect
compound
thu
identifi
ellag
acid
figur
interpret
proton
carbon
signal
larg
consist
nawwar
souleman
ellag
acid
identifi
basi
follow
evid
green
amorph
power
uv
meoh
nm
ftir
eim
ev
mz
rel
intens
nmr
mhz
arh
nmr
mhz
antivir
activ
l
speciosa
leafderiv
materi
toward
three
hrv
test
evalu
srb
method
use
cpe
reduct
brief
hela
cell
seed
onto
microtit
plate
concentr
cell
per
well
day
cultur
medium
remov
plate
wash
phosphatebuff
salin
pb
ph
subsequ
dilut
viru
suspens
contain
viru
stock
ad
produc
appropri
cpe
within
day
infect
follow
addit
mem
supplement
mm
contain
four
five
concentr
test
materi
dimethylsulfoxid
dmso
base
preliminari
test
result
cultur
plate
incub
day
wash
pb
cold
aceton
ad
well
left
min
aceton
solut
remov
plate
left
dri
oven
volum
wv
srb
acet
acid
solut
ad
well
left
room
temperatur
min
unbound
srb
remov
plate
wash
five
time
acet
acid
dri
left
dri
oven
day
bound
srb
solubil
mm
unbuff
trisbas
solut
plate
left
tabl
min
absorb
read
nm
use
versamax
micropl
reader
molecular
devic
sunnyval
ca
refer
absorb
nm
ribavirin
serv
posit
control
similarli
prepar
neg
control
consist
dmso
solut
viral
inhibit
rate
calcul
use
follow
formula
odtv
odcv
odcd
odcv
odtv
optic
densiti
measur
given
concentr
test
materi
hrv
infect
cell
odcv
optic
densiti
measur
control
untreat
hrv
infect
cell
odcd
optic
densiti
measur
control
untreat
hrv
uninfect
cell
hela
cell
seed
onto
microtit
plate
state
previous
cultur
medium
remov
plate
replac
media
contain
differ
concentr
test
materi
dmso
base
preliminari
test
result
incub
day
cytotox
test
materi
hela
cell
evalu
use
srb
assay
state
previous
effect
ellag
acid
ribavirin
infect
particl
evalu
describ
previous
choi
et
al
approxim
twofold
quantiti
valu
test
compound
appli
preincub
ellag
acid
ribavirin
h
monolay
hela
cell
infect
pretreat
untreat
h
unbound
viru
remov
wash
well
pb
cell
incub
fresh
medium
supplement
without
test
compound
day
srb
test
antivir
activ
carri
state
previous
timeofaddit
effect
ellag
acid
test
accord
method
choi
et
al
brief
monolay
hela
cell
seed
onto
microtit
plate
state
previous
wash
pb
ellag
acid
ad
onto
cultur
cell
h
h
h
infect
ribavirin
serv
posit
control
similarli
prepar
day
srb
test
antivir
activ
carri
state
previous
evalu
level
gene
express
quantit
realtim
revers
transcriptionpcr
rtpcr
sybr
green
dye
perform
infect
noninfect
cultur
hela
cell
grown
corn
cell
cultur
flask
corn
ny
treat
ellag
acid
ribavirin
incub
day
total
rna
extract
cultur
cell
use
rneasi
plu
mini
kit
qiagen
hilden
germani
accord
manufactur
instruct
contamin
genom
dna
remov
use
rnasefre
dnase
promega
madison
wi
complementari
dna
synthes
use
total
rna
revers
transcript
reaction
use
superscript
firststrand
synthesi
kit
invitrogen
carlsbad
ca
quantit
rtpcr
perform
plate
use
steponeplu
realtim
pcr
system
appli
biosystem
foster
ca
reaction
mixtur
consist
maxima
sybr
greenrox
qpcr
master
mix
thermo
scientif
foster
ca
forward
revers
primer
pmol
complementari
dna
ng
doubledistil
water
final
volum
oligonucleotid
pcr
primer
assay
id
assay
id
purchas
appli
biosystem
pcr
condit
follow
min
min
cycl
mrna
express
level
target
gene
normal
mrna
express
level
housekeep
gene
analyz
method
use
stepon
softwar
dataassist
softwar
appli
biosystem
cytotox
express
cytotox
concentr
compound
reduc
viabil
cell
control
fifti
percent
inhibitori
concentr
defin
compound
concentr
requir
reduc
viral
cpe
control
valu
calcul
use
graphpad
prism
softwar
graphpad
softwar
la
jolla
ca
therapeut
index
determin
ratio
result
express
mean
sd
triplic
sampl
three
independ
experi
statist
analys
carri
use
sa
program
sa
institut
cari
nc
data
two
group
analyz
student
ttest
multipl
group
analyz
oneway
analysi
varianc
bonferroni
multipl
comparison
test
antivir
activ
natur
ellag
acid
commerci
pure
ellag
acid
ribavirin
significantli
differ
toward
f
df
p
f
df
p
f
df
p
tabl
base
valu
natur
ellag
acid
pure
ellag
acid
differ
significantli
antivir
activ
toward
three
hrv
indic
activ
methanolextract
ellag
acid
pure
due
ellag
acid
natur
ellag
acid
time
toxic
toward
ribavirin
respect
ellag
acid
ribavirin
toward
hela
cell
srb
assay
effect
ellag
acid
ribavirin
infect
particl
likewis
examin
figur
inhibit
rate
preincub
ellag
acid
ribavirin
respect
continu
presenc
ellag
acid
ribavirin
infect
led
signific
increas
inhibit
rate
investig
mode
action
ellag
acid
ribavirin
time
cours
inhibit
compound
differ
period
infect
likewis
investig
figur
treatment
ellag
acid
consider
suppress
hrv
infect
ad
viru
inocul
h
inhibit
inhibit
rate
ellag
acid
declin
less
ad
either
prior
h
post
h
infect
howev
inhibitori
effect
ribavirin
infect
occur
h
rna
replic
level
hela
cell
remark
inhibit
cell
cultur
treat
ellag
acid
figur
rna
replic
level
reduc
fold
compar
level
cell
cultur
without
ellag
acid
current
vitro
studi
indic
materi
deriv
l
speciosa
leav
exhibit
antivir
activ
select
toward
three
rhinovirus
plant
grow
wide
tropic
countri
includ
philippin
india
malaysia
china
australia
popular
folk
medicin
southeast
asia
l
speciosa
leav
contain
acet
alkaloid
sterol
tannin
triterpenoid
excel
antidiabet
properti
standard
extract
l
speciosa
leav
well
note
variou
compound
includ
phenol
terpenoid
alkaloid
exist
plant
jointli
independ
contribut
antivir
efficaci
mani
plant
constitu
manifest
antivir
activ
toward
differ
virus
propos
altern
convent
antivir
drug
antihrv
constitu
deriv
plant
includ
alkaloid
eg
arborinin
ribalinin
glaucin
coumarin
eg
daphnoretin
methyl
ether
farnesiferol
b
c
flavonoid
eg
three
relat
compound
effect
concentr
chrysosplenol
other
minimum
effect
dose
chrysosplenol
c
terpenoid
eg
acid
orobol
organ
acid
eg
raoulic
acid
gallic
acid
thiosulfin
allicin
allyl
methylthiosulfin
report
hrv
capsidbind
compound
toward
hrv
serotyp
show
exist
group
b
base
wide
rang
suscept
antivir
compound
current
studi
antivir
principl
determin
tannin
ellag
acid
constitu
exhibit
antivir
activ
toward
group
group
b
ellag
acid
toward
three
hrv
although
natur
compound
state
previous
ellag
acid
exhibit
greater
antivir
activ
ribavirin
toward
three
hrv
high
select
origin
find
indic
materi
deriv
l
speciosa
leav
hold
promis
develop
novel
effect
natur
occur
antivir
agent
two
differ
hrv
group
b
addit
ellag
acid
report
possess
antihiv
activ
inhibit
hiv
proteas
orobol
l
speciosa
leav
also
known
broadspectrum
antivir
activ
toward
variou
hrv
includ
group
b
well
pleconarilresist
investig
mode
antivir
action
natur
occur
compound
may
contribut
develop
select
hrv
therapeut
altern
novel
target
site
mode
antihrv
action
plant
secondari
substanc
well
review
rolling
schmidtk
target
viru
molecul
like
specif
less
toxic
narrow
spectrum
virus
higher
risk
creat
resist
virus
contrari
chemic
target
cellular
molecul
may
possess
broader
antivir
activ
spectrum
less
risk
develop
viru
resist
may
toxic
host
cell
current
studi
ellag
acid
interact
particl
preexposur
viru
constitu
alter
infect
particl
base
timeofaddit
experi
ellag
acid
significantli
suppress
infect
ad
viru
inocul
h
h
h
later
find
suggest
ellag
acid
may
directli
interact
human
cell
earli
stage
hrv
infect
protect
cell
viru
destruct
addit
rtpcr
analysi
reveal
ellag
acid
strongli
inhibit
rna
replic
hela
system
suggest
ellag
acid
inhibit
viru
replic
target
cellular
molecul
rather
viru
molecul
detail
test
need
fulli
understand
antihrv
mode
action
ellag
acid
l
speciosa
leafderiv
prepar
contain
ellag
acid
could
use
antivir
agent
prevent
treatment
hrv
infect
antivir
action
ellag
acid
may
indic
least
one
pharmacolog
action
l
speciosa
practic
use
l
speciosa
leafderiv
prepar
novel
antihrv
product
proceed
research
need
establish
human
safeti
whether
activ
exert
vivo
consumpt
l
speciosa
leafderiv
product
human
histor
tea
plant
leav
use
treatment
diabet
mellitu
philippin
rat
fed
ellag
acid
dose
high
mgday
day
caus
sign
system
toxic
lastli
detail
test
need
understand
improv
antihrv
potenc
stabil
eventu
commerci
develop
atcc
american
type
cultur
collect
cytotox
concentr
cell
cultur
infect
dose
cpe
cytopath
effect
dmso
dimethylsulfoxid
hrv
human
rhinoviru
inhibitori
concentr
mem
minimum
essenti
medium
pb
phosphatebuff
salin
rtpcr
revers
transcriptionpcr
srb
sulforhodamin
b
tlc
thin
layer
chromatographi
author
declar
compet
interest
yja
conceiv
project
supervis
studi
swp
mjk
jyy
design
experiment
protocol
carri
test
analyz
data
wrote
first
draft
manuscript
hjc
help
develop
protocol
analyz
data
yja
evalu
result
wrote
final
draft
manuscript
author
read
approv
final
manuscript
prepubl
histori
paper
access
http
